Kiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01

Kiromic BioPharmaDec 12 13:00

Financial Crime Weekly: CEO Sentenced To 51 Months In Prison, Kiromic BioPharma Charged With Failure To Disclose Material Information

BenzingaDec 7 21:00

Express News | Kiromic Biopharma Inc - SEC Declines to Impose Civil Penalties on Kiromic Biopharma

BreakingsDec 4 00:03

SEC Charges Kiromic BioPharma and Two Former C-Suite Executives With Misleading Investors About Status of FDA Reviews

newsfileDec 3 22:19

Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation

Kiromic BioPharmaDec 3 13:00

Kiromic BioPharma | 10-Q: Q3 2024 Earnings Report

SECNov 9 03:54 · Announcements